AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 279: H1941-H1948, 2000;
0363-6135/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pyle, W. G.
Right arrow Articles by Hofmann, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pyle, W. G.
Right arrow Articles by Hofmann, P. A.
Vol. 279, Issue 4, H1941-H1948, October 2000

Cardioprotection with kappa -opioid receptor stimulation is associated with a slowing of cross-bridge cycling

W. G. Pyle, T. D. Smith, and P. A. Hofmann

Department of Physiology, University of Tennessee, Memphis, Tennessee 38163

Opioid and alpha -adrenergic receptor activation protect the heart from ischemic damage. One possible intracellular mechanism to explain this is that an improvement in ATP availability contributes to cardioprotection. We tested this hypothesis by correlating postischemic left ventricular developed pressure (LVDP) and myofibrillar Ca2+-dependent actomyosin Mg2+-ATPase from isolated rat hearts treated with the kappa -opioid receptor agonist U-50488H (1 µM) or the alpha -adrenergic receptor agonist phenylephrine (10 µM) + propranolol (3 µM). Preischemic treatment with U-50488H or phenylephrine + propranolol improved postischemic LVDP recovery by 25-30% over control hearts. Ca2+-dependent actomyosin Mg2+-ATPase was found to be 20% lower in both U-50488H- and phenylephrine + propranolol-treated hearts compared with control hearts. The kappa -opioid receptor antagonist nor-binaltorphimine (1 µM) abolished the effects of U-50488H on postischemic LVDP and actomyosin Mg2+-ATPase activity. Reduced actomyosin ATP utilization was also suggested in single ventricular myocytes treated with either U-50488H or the protein kinase C activator, phorbol 12-myristate 13-acetate (PMA), because U-50488H and PMA lowered maximum velocity of unloaded shortening by 15-25% in myocytes. U-50488H and phenylephrine + propranolol treatment both resulted in increased phosphorylation of troponin I and C protein. These findings are consistent with the hypothesis that kappa -opioid and alpha -adrenergic receptors decrease actin-myosin cycling rate, leading to a conservation of ATP and cardioprotection during ischemia.

preconditioning; U-50488H; myofibrillar magnesium adenosine 5'-triphosphatase; metabolic slowing; myocytes; cardiac; velocity of shortening; left ventricular developed pressure; troponin I; C protein


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. E. Shaw, P. Wood, J. Kulpa, F. H. Yang, A. J. Summerlee, and W. G. Pyle
Relaxin alters cardiac myofilament function through a PKC-dependent pathway
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H29 - H36.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. A. Hofmann, M. Israel, Y. Koseki, J. Laskin, J. Gray, A. Janik, T. W. Sweatman, and L. Lothstein
N-Benzyladriamycin-14-valerate (AD 198): A Non-Cardiotoxic Anthracycline That Is Cardioprotective through PKC-{epsilon} Activation
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 658 - 664.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Cao, L. Liu, and D. M. Van Winkle
Met5-enkephalin-induced cardioprotection occurs via transactivation of EGFR and activation of PI3K
Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1955 - H1964.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. M. Metzger and M. V. Westfall
Covalent and Noncovalent Modification of Thin Filament Action: The Essential Role of Troponin in Cardiac Muscle Regulation
Circ. Res., February 6, 2004; 94(2): 146 - 158.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Chen, R. Rajashree, Q. Liu, and P. Hofmann
Acute p38 MAPK activation decreases force development in ventricular myocytes
Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2578 - H2586.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Cao, L. Liu, and D. M. Van Winkle
Activation of {delta}- and {kappa}-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels
Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1032 - H1039.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. G. Pyle, Y. Chen, and P. A. Hofmann
Cardioprotection through a PKC-dependent decrease in myofilament ATPase
Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1220 - H1228.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. G. Pyle, M. P. Sumandea, R. J. Solaro, and P. P. De Tombe
Troponin I serines 43/45 and regulation of cardiac myofilament function
Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1215 - H1224.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. G. Pyle, J. W. Lester, and P. A. Hofmann
Effects of {kappa}-opioid receptor activation on myocardium
Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H669 - H678.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online